Drug Profile
Trastuzumab subcutaneous - Roche
Alternative Names: Herceptin Hylecta; Herceptin SC; Hyaluronidase-trastuzumab; Reformulated Herceptin - Roche; RG597 (SC formulation) - Roche; Trastuzumab SC; Trastuzumab-hyaluronidaseLatest Information Update: 05 Jun 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HER2 positive breast cancer
- No development reported Breast cancer
Most Recent Events
- 28 Jul 2022 Trastuzumab subcutaneous is still in phase III trials for Breast cancer (Early-stage disease) in Slovenia, Slovakia, Lithuania, Romania, France, Czech Republic, Bulgaria (SC)
- 10 May 2022 Launched for Her2 positive Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in Italy (SC)
- 10 May 2022 Launched for Her2 positive Breast cancer (Early-stage disease) in Italy (SC)